Long-Term Follow Up Study of Subjects Previously Administered HMI 102

An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects With PAH Deficiency Previously Administered HMI 102

An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102

This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH Deficiency Previously Administered HMI 102. Subjects will have already received a single dose of HMI-102 administered intravenously

Inclusion Criteria:

• Subject was previously administered HMI 102.
• Subject is able to understand the purpose and risks of the study and is willing to provide informed consent.
• Subject is able to comply with all study procedures and long-term follow-up.

Exclusion Criteria:

• Participation in the study is not in the subject's best interest, in the opinion of the Investigator.